search
Back to results

SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection

Primary Purpose

Peritonitis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
duration of antibiotics
duration of antibiotics
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peritonitis focused on measuring intraabdominal, peritonitis, sepsis, duration, antibiotics

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age ≥ 16 at some sites,(≥ 18 at UVA)
  • ability to obtain informed consent from the subject or surrogate
  • Presence of an intraabdominal infection requiring any duration of hospitalization and managed with open, laparoscopic, or percutaneous intervention.
  • A peripheral white blood cell count of > 11,000/mm and/or temperature ≥ 38.0 C with in 24 hours or gastrointestinal dysfunction sufficient to prevent intake of normal diet within 24hrs of initial operative or percutaneous intervention.
  • Adequate source control in the opinion of the local investigator and PI. Source control is defined as any procedure that stops the ongoing contamination of the peritoneal cavity and removes the majority of the contaminated intraperitoneal contents to the extent that no further acute interventions are felt to be necessary.

Exclusion Criteria:

  • age < 16 years at some sites(< 18 at UVA)
  • Inability to obtain consent from the patient, parents, or surrogate
  • Lack of adequate source control in the opinion of the local investigator or overall PI ( Robert Sawyer)
  • High likelihood of death within 72 hours of initial intervention in the opinion of the local investigator or principal investigator
  • Lack of any clinical improvement within 72 hours of initial intervention in the opinion of the local investigator or principal investigator.
  • Planned relaparotomy
  • Perforated gastric ulcer or duodenal ulcer treated within 24hours of the onset of symptoms
  • Traumatic injury to the bowel (including iatrogenic or intra-operative) treated within 12 hours of injury
  • Non-perforated, non-gangrenous appendicitis or cholecystitis
  • Gangrenous appendicitis or peritonitis without confirmatory cultures or with cultures without bacterial or fungal growth
  • Ischemic or necrotic intestine without perforation and without positive bacterial or fungal cultures
  • Intraabdominal infection associated with active necrotizing pancreatitis
  • Primary (spontaneous) bacterial peritonitis
  • Intraabdominal infection associated with an indwelling continuous ambulatory peritoneal dialysis catheter.
  • Primary skin closure of an open surgical incision in the presence of diffuse, non-localized peritonitis. Laparoscopic port sites ≥ 2cm may be closed
  • Pregnancy
  • Prior enrollment in this study
  • Enrollment in another therapeutic trial

Sites / Locations

  • Maricopa Medical Center-Phoenix
  • University of California Davis
  • University of California San Diego
  • University of California San Francisco
  • University of Miami
  • Univestity of Kansas
  • Louisville-VA
  • Louisville-University Hospital
  • Johns Hopkins
  • Brigham and Womens
  • Univeristy of Michigan
  • Washington Universtiy
  • Wake Forest University
  • Case Western
  • Ohio State University
  • Pittsburgh VA
  • University of South Carolina
  • Universtiy of Texas San Antonio
  • University of Virginia
  • Medical College of Virginia-Virginia Commonwealth University Hospital
  • University of Washington-Harborview
  • University of Washington - University Hospital
  • St Michael's

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

1

2

Arm Description

antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function

4 +/- 1 days of antibiotics

Outcomes

Primary Outcome Measures

The primary endpoint will be percentage failure conditioned by assigned duration of antibiotic therapy (intent to treat analysis).

Secondary Outcome Measures

Failure rate for clinically evaluable patients receiving the appropriate duration of antibiotics
failure rate for microbiologically evaluable patients
rate of need for reintervention in the abdomen
rate of surgical site infection
rate of death within 30 days
duration of hospitalization
rate of intraabdominal or surgical site failure due to antimicrobial-resistant pathogens
rate of any subsequent infection at a site other than the abdomen or the surgical site
rate of infection at a non-abdominal, non-surgical site with a resistant organism
rate of Clostridium difficile infection

Full Information

First Posted
April 10, 2008
Last Updated
May 18, 2018
Sponsor
University of Virginia
Collaborators
National Institute of General Medical Sciences (NIGMS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00657566
Brief Title
SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
Official Title
SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Virginia
Collaborators
National Institute of General Medical Sciences (NIGMS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The major hypothesis to be tested is that the treatment of intraabdominal infections that have been adequately treated operatively or by percutaneous techniques with three to five days of antibiotics will result in outcomes equivalent to the current standard where treatment is carried out until the patient has returned to normal (normal white blood cell count, temperature, and intestinal function), and that patients treated for three to five days will receive fewer days of antibiotics than the control group that has traditionally received seven to 14 days of treatment.
Detailed Description
Overall, this is a prospective, randomized, single-blinded (analysis), fifteen-center study using intent to treat analysis. Patients will be identified and after informed consent is obtained, will be randomized to receive antibiotics for 3 to 5 days (4 ± 1 days) after the initial surgical or percutaneous intervention or antibiotics until two calendar days after the patient's white blood cell count, systemic temperature, and gastrointestinal function have normalized (maximum of 10 days). The primary endpoint is the composite rate of in-hospital death and/or recurrence of intraabdominal infection and/or occurrence of surgical site (wound) infection. Secondary endpoints include the occurrence of any infection at any site and infection with antibiotic-resistant pathogens. Patient data through the thirty days following the initial intervention or until hospital discharge (whichever is longer) will be tracked

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peritonitis
Keywords
intraabdominal, peritonitis, sepsis, duration, antibiotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
518 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
Arm Title
2
Arm Type
Experimental
Arm Description
4 +/- 1 days of antibiotics
Intervention Type
Other
Intervention Name(s)
duration of antibiotics
Other Intervention Name(s)
short course
Intervention Description
4 +/- 1 days of antibiotics
Intervention Type
Other
Intervention Name(s)
duration of antibiotics
Other Intervention Name(s)
long course
Intervention Description
active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
Primary Outcome Measure Information:
Title
The primary endpoint will be percentage failure conditioned by assigned duration of antibiotic therapy (intent to treat analysis).
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Failure rate for clinically evaluable patients receiving the appropriate duration of antibiotics
Time Frame
30 days
Title
failure rate for microbiologically evaluable patients
Time Frame
30 days
Title
rate of need for reintervention in the abdomen
Time Frame
30 days
Title
rate of surgical site infection
Time Frame
30 days
Title
rate of death within 30 days
Time Frame
30 days
Title
duration of hospitalization
Time Frame
30 days
Title
rate of intraabdominal or surgical site failure due to antimicrobial-resistant pathogens
Time Frame
30 days
Title
rate of any subsequent infection at a site other than the abdomen or the surgical site
Time Frame
30 days
Title
rate of infection at a non-abdominal, non-surgical site with a resistant organism
Time Frame
30 days
Title
rate of Clostridium difficile infection
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age ≥ 16 at some sites,(≥ 18 at UVA) ability to obtain informed consent from the subject or surrogate Presence of an intraabdominal infection requiring any duration of hospitalization and managed with open, laparoscopic, or percutaneous intervention. A peripheral white blood cell count of > 11,000/mm and/or temperature ≥ 38.0 C with in 24 hours or gastrointestinal dysfunction sufficient to prevent intake of normal diet within 24hrs of initial operative or percutaneous intervention. Adequate source control in the opinion of the local investigator and PI. Source control is defined as any procedure that stops the ongoing contamination of the peritoneal cavity and removes the majority of the contaminated intraperitoneal contents to the extent that no further acute interventions are felt to be necessary. Exclusion Criteria: age < 16 years at some sites(< 18 at UVA) Inability to obtain consent from the patient, parents, or surrogate Lack of adequate source control in the opinion of the local investigator or overall PI ( Robert Sawyer) High likelihood of death within 72 hours of initial intervention in the opinion of the local investigator or principal investigator Lack of any clinical improvement within 72 hours of initial intervention in the opinion of the local investigator or principal investigator. Planned relaparotomy Perforated gastric ulcer or duodenal ulcer treated within 24hours of the onset of symptoms Traumatic injury to the bowel (including iatrogenic or intra-operative) treated within 12 hours of injury Non-perforated, non-gangrenous appendicitis or cholecystitis Gangrenous appendicitis or peritonitis without confirmatory cultures or with cultures without bacterial or fungal growth Ischemic or necrotic intestine without perforation and without positive bacterial or fungal cultures Intraabdominal infection associated with active necrotizing pancreatitis Primary (spontaneous) bacterial peritonitis Intraabdominal infection associated with an indwelling continuous ambulatory peritoneal dialysis catheter. Primary skin closure of an open surgical incision in the presence of diffuse, non-localized peritonitis. Laparoscopic port sites ≥ 2cm may be closed Pregnancy Prior enrollment in this study Enrollment in another therapeutic trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert G Sawyer, MD
Organizational Affiliation
University of Virginia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maricopa Medical Center-Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85008
Country
United States
Facility Name
University of California Davis
City
Sacramento
State/Province
California
Country
United States
Facility Name
University of California San Diego
City
San Diego
State/Province
California
Country
United States
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
Country
United States
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Univestity of Kansas
City
Kansas City
State/Province
Kansas
Country
United States
Facility Name
Louisville-VA
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40121
Country
United States
Facility Name
Louisville-University Hospital
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Johns Hopkins
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Facility Name
Brigham and Womens
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Univeristy of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48502
Country
United States
Facility Name
Washington Universtiy
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Wake Forest University
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
Case Western
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
Country
United States
Facility Name
Pittsburgh VA
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15206
Country
United States
Facility Name
University of South Carolina
City
Columbia
State/Province
South Carolina
Country
United States
Facility Name
Universtiy of Texas San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Medical College of Virginia-Virginia Commonwealth University Hospital
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
University of Washington-Harborview
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
University of Washington - University Hospital
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
Facility Name
St Michael's
City
Toronto
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
17083308
Citation
Hedrick TL, Evans HL, Smith RL, McElearney ST, Schulman AS, Chong TW, Pruett TL, Sawyer RG. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt). 2006 Oct;7(5):419-32. doi: 10.1089/sur.2006.7.419.
Results Reference
background
PubMed Identifier
25992746
Citation
Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, Cook CH, O'Neill PJ, Mazuski JE, Askari R, Wilson MA, Napolitano LM, Namias N, Miller PR, Dellinger EP, Watson CM, Coimbra R, Dent DL, Lowry SF, Cocanour CS, West MA, Banton KL, Cheadle WG, Lipsett PA, Guidry CA, Popovsky K; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015 May 21;372(21):1996-2005. doi: 10.1056/NEJMoa1411162. Erratum In: N Engl J Med. 2018 Jan 25;:null.
Results Reference
derived

Learn more about this trial

SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection

We'll reach out to this number within 24 hrs